Combining Low Doses of Four Non-Psychoactive Cannabinoids Reduces Gut Pain in Mice with Colitis | Research

The takeaway

CBD and CBG individually reduced visceral pain from colitis in mice, and a combination of four non-psychoactive cannabinoids at subtherapeutic doses achieved the same pain relief through sodium and calcium channel mechanisms.

gastroenterologists, IBD patients, cannabinoid pharmacologists, pain researchers

What the researchers found

Single injections of CBD or CBG (10 mg/kg) each reduced visceral hypersensitivity and spinal cord c-Fos activation in colitis mice. A combination of CBD (5 mg/kg) with CBC, CBDV, and CBG (each 1 mg/kg) — all at individually subtherapeutic doses — also reduced visceral pain. The combination acted through voltage-gated sodium and calcium channels (particularly Cav2.2) but not Cav3.2 or potassium channels.

Why it matters

IBD patients frequently report abdominal pain as their most disabling symptom. This study demonstrates that a mixture of non-psychoactive cannabinoids can provide pain relief at doses where individual compounds are ineffective — a true entourage effect with identified molecular targets.

The numbers in context

CBD 10 mg/kg or CBG 10 mg/kg individually effective. Combination: CBD 5 mg/kg + CBC 1 mg/kg + CBDV 1 mg/kg + CBG 1 mg/kg (all subtherapeutic individually). Pain relief without altering colitis inflammation. Targets: Nav and Cav2.2 channels.

How the study worked

Mouse model of dextran sulfate sodium colitis-induced visceral hypersensitivity. Single-injection cannabinoid administration. Patch-clamp electrophysiology on dorsal root ganglia neurons and recombinant ion channels to identify antinociceptive targets.

What this study cannot tell us

Mouse model of colitis may not fully recapitulate human IBD pain. Single-injection design does not assess chronic use. Subtherapeutic doses were defined within this model only. Did not reduce inflammation, only pain.

How to read the evidence

Well-designed preclinical study with electrophysiological mechanism identification, but mouse model and single-dose design limit clinical translation.

When this study was published

2025 publication.

The bigger picture

The entourage effect is often invoked but rarely demonstrated with specific mechanisms. This study provides concrete evidence that combining cannabinoids at low doses produces analgesic effects through identified ion channel targets, supporting multi-cannabinoid product development.

Questions still open

Would this cannabinoid combination work for chronic IBD pain management in humans?
Could multi-cannabinoid formulations replace opioids for visceral pain?

Common questions

Can cannabinoids help with IBD pain?

In this mouse study, CBD and CBG each reduced colitis-related visceral pain, and a low-dose combination of four non-psychoactive cannabinoids (CBD, CBG, CBC, CBDV) was equally effective. None of the treatments altered the underlying colitis inflammation.

What is the cannabinoid entourage effect?

This study demonstrated the entourage effect: four cannabinoids at individually ineffective doses produced significant pain relief when combined. The mechanism involved voltage-gated sodium and calcium channels in pain-sensing neurons.

Read the original research

Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.

The Journal of pharmacology and experimental therapeutics, 392(3), 103389

View on PubMed ↗Publisher’s paper ↗

Citation

Svendsen, Kristofer; Bradaia, Amyaouch; Gandini, Maria A; Defaye, Manon; Matisz, Chelsea; Abdullah, Nasser S; Gruber, Aaron; Zamponi, Gerald W; Sharkey, Keith A; Altier, Christophe. (2025). Entourage effects of nonpsychotropic cannabinoids on visceral sensitivity in experimental colitis.. The Journal of pharmacology and experimental therapeutics, 392(3), 103389. https://doi.org/10.1016/j.jpet.2025.103389